Online citations, reference lists, and bibliographies.
← Back to Search

Conventional Treatment And Its Effect On Survival Of Malignant Pleural Mesothelioma In Western Australia.

A. Musk, Stephen D. Woodward
Published 1982 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Analysis of the survival of all 81 cases of pathologically confirmed malignant pleural mesothelioma in Western Australia between January 1957 and December 1980 has revealed a median survival from diagnosis of 5.1 months (mean 7.8 months). The average time between presentation and diagnosis was 3.4 months. Survival was better in younger subjects and subjects selected for surgery but was unrelated to sex, symptoms at onset, history of asbestos exposure, tumour morphology, therapy other than surgery or year of presentation. The selection of subjects at earlier clinical stages for surgical intervention is considered to account for their longer survival. The outlook for patients with this disease remains poor and there is still no optimism for future advances in therapy.
This paper references

This paper is referenced by
Predicting survival in malignant mesothelioma
A. Musk (2011)
HLA antigen expression and malignant mesothelioma.
T. Christmas (1991)
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
Management of malignant pleural mesothelioma.
S. West (2006)
Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
S. Neragi-Miandoab (2008)
Malign Plevral Mezotelyoma Hücre Hattinda Histon Asetil Transferaz İnhibitörü Olan Anakardik Asitin Sisplatin Cevabini Arttirici Etkisi
H. Onen (2013)
Management of malignant pleural mesothelioma
A. Nowak (2007)
Chemosensitivity and cytokine sensitivity of malignant mesothelioma
R. Bowman (2004)
The Wittenoom legacy.
A. W. Musk (2019)
Predictions of future cases of asbestos‐related disease among former miners and millers of crocidolite in Western Australia
Nicholas H. de Klerk (1989)
Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.
Irina Caminschi (1999)
Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma.
L. S. Manning (1989)
Intralesional Cytokine Therapy in Cancer: A Pilot Study of GM‐CSF Infusion in Mesothelioma
J. A. Davidson (1998)
Retinol supplementation and mesothelioma incidence in workers earlier exposed to blue asbestos (Crocidolite) at Wittenoom, Western Australia
H. Alfonso (2010)
Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study.
C. J. Lindén (1996)
Interleukin-12 induces an effective antitumor response in malignant mesothelioma.
Irina Caminschi (1998)
Effect of Interferon-α2a Malignant Mesothelioma
T. Christmas (1993)
Mesothelioma as a Marker for Asbestos-Related Lung Disease in Victoria
S. Begg (2001)
Current chemotherapeutic treatment of malignant pleural mesothelioma
A. Nowak (2004)
Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.
J. Upham (1993)
Potential for cytokine therapy of malignant mesothelioma.
D. FitzPatrick (1995)
Vitamin A and cancer prevention I: Observations in workers previously exposed to asbestos at Wittenoom, Western Australia
A. Musk (1998)
Cisplatin a nd G emcitabine T reatment f or M alignant Mesothelioma: A P hase I I S tudy
J. Dewar (1999)
Survival after conservative (palliative) management of pleural malignant mesothelioma
N. Merritt (2001)
Plasma vitamin concentrations and incidence of mesothelioma and lung cancer in individuals exposed to crocidolite at Wittenoom, Western Australia
H. Alfonso (2006)
Semantic Scholar Logo Some data provided by SemanticScholar